Skip to content
value.today
PepGen Inc. logo

PepGen Inc.

PEPG
$175 Mmarket cap on Oct 26, 2026-6.2% since Jan 2024
Compare
World rank
#16,755
Revenue
—
For year ending December-2025
Net income
$-90 M
SEC filing
Employees
—

PepGen Inc. in brief

PepGen Inc. is a listed company in the Biotechnology industry, based in Boston, Massachusetts, USA. It was founded in 2018. Its market value was $175 M on 26 October 2026, which makes it the 16,755th largest listed company in the world and the 3,232nd largest in the USA on this site. James G. McArthur is its chief executive. Its shares trade under the symbol PEPG (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About PepGen Inc.

PepGen Inc is a clinical stage biotechnology company focused on advancing the next generation of oligonucleotide therapeutics with the goal of transforming the treatment of severe neuromuscular and neurologic diseases. The headquarters is in Massachusetts.

PepGen Inc. timeline

3 events, 2018–2022
  1. 2018
  2. 🏁
    · approximate
    Founded
  3. 2020
  4. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  5. 2022
  6. 🔔
    Initial public offering on Nasdaq
    Final prospectus filed with the SEC on 9 May 2022; shares registered for exchange trading on 3 May 2022.

Events of PepGen Inc. from the company record and SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$106 M$212 M$318 M$424 M2023202420252026

World rank over time

▼ down 2,140 places since 2022
2022-12-25: #14653#14,65320222023-07-30: #19668#19,66820232024-01-05: #18295#18,29520242026-03-08: #7715#7,71520262026-08-01: #15313#15,31320262026-10-06: #17076#17,07620262026-10-26: #16793#16,7932026

Rank in USA: #3,003 (Dec 2022) · #3,874 (Jul 2023) · #3,306 (Jan 2024) · #1,369 (Mar 2026) · #3,083 (Aug 2026) · #3,244 (Oct 2026) · #3,236 (Oct 2026)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
—
Price / book
1.2×
Free cash flow yield
-46.9%
Net margin
—
Operating margin
—
Return on equity
-60.8%
Liabilities / assets
15.2%

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2021: revenue —, net income $-27M—FY21Fiscal year ending Dec 2022: revenue —, net income $-69M—FY22Fiscal year ending Dec 2023: revenue —, net income $-79M—FY23Fiscal year ending Dec 2024: revenue —, net income $-90M—FY24Fiscal year ending Dec 2025: revenue —, net income $-90M—FY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025——$-94M$-90M—
Dec 2024——$-98M$-90M—
Dec 2023——$-85M$-79M—
Dec 2022——$-68M$-69M—
Dec 2021——$-27M$-27M—

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-82M$0M$-82M$-2.12—
Dec 2024$-82M$1M$-83M$-2.85—
Dec 2023$-69M$3M$-72M$-3.30—
Dec 2022$-59M$4M$-63M$-4.42—
Dec 2021$-23M$1M$-23M$-30.27—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue —, net income $-22M—Dec ’24Three months to Mar 2025: revenue —, net income $-30M—Mar ’25Three months to Jun 2025: revenue —, net income $-23M—Jun ’25Three months to Sep 2025: revenue —, net income $-18M—Sep ’25Three months to Dec 2025 (from the annual report): revenue —, net income $-18M—Dec ’25Three months to Mar 2026: revenue —, net income $-18M—Mar ’26Three months to Jun 2026: revenue —, net income $-18M—Jun ’26Three months to Sep 2026: revenue —, net income $-19M—Sep ’26

Latest quarter to Sep 2026: revenue —, net income $-19M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of PepGen Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
—
Operating income
$-94 M
Net income
$-90 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$174 M
Total liabilities
$26 M
Total equity
$147 M

As of December-2025

Top 84 institutional investors in PepGen Inc.#

As of Sep 30, 2026
84 institutions held 54.3 M shares (about 78.4% of the shares outstanding) on Sep 30, 2026. The ten largest hold 61.2%. Source: SEC Form 13F filings, filed through Nov 17, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in PepGen Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Ra Capital Management, L.P.20,064,5450 (0.00%)28.97%$49 MNov 16, 2026
2Commodore Capital LP4,475,0000 (0.00%)6.46%$11 MNov 16, 2026
3Viking Global Investors LP3,482,4340 (0.00%)5.03%$8 MNov 16, 2026
4Laurion Capital Management LP2,750,8550 (0.00%)3.97%$7 MOct 30, 2026
5Vivo Capital, LLC2,325,0000 (0.00%)3.36%$6 MNov 13, 2026
6Marshall Wace, LLP2,049,112+1,182,120 (+136.35%)2.96%$5 MNov 13, 2026
7Rosalind Advisors, Inc.2,000,000+1,650,000 (+471.43%)2.89%$5 MNov 16, 2026
8Vanguard Capital Management LLC1,977,015+41,095 (+2.12%)2.85%$5 MNov 13, 2026
9AWM Investment Company, Inc.1,806,419+1,206,419 (+201.07%)2.61%$4 MNov 13, 2026
10ADAR1 Capital Management, LLC1,440,874-1,150,211 (-44.39%)2.08%$3 MNov 16, 2026
11BlackRock, Inc.1,346,219+41,957 (+3.22%)1.94%$3 MNov 13, 2026
12Millennium Management LLC1,138,667-648,098 (-36.27%)1.64%$3 MNov 16, 2026
13Renaissance Technologies LLC880,758-639,488 (-42.06%)1.27%$2 MNov 12, 2026
14Ikarian Capital, LLC693,539+246,374 (+55.10%)1.00%$2 MNov 16, 2026
15Squadron Capital Management LLC600,000New0.87%$1 MNov 16, 2026
16Monimus Capital Management, LP587,6880 (0.00%)0.85%$1 MNov 16, 2026
17Susquehanna International Group, LLP531,055+455,639 (+604.17%)0.77%$1 MNov 16, 2026
18Boothbay Fund Management, LLC499,512+133,371 (+36.43%)0.72%$1 MNov 16, 2026
19Gsa Capital Partners LLP487,558-365,294 (-42.83%)0.70%$1 MNov 16, 2026
20Geode Capital Management, LLC484,783-38,690 (-7.39%)0.70%$1 MNov 6, 2026
21Citadel Advisors LLC399,251-259,130 (-39.36%)0.58%$1 MNov 16, 2026
22Creek Drive Management Group LLC370,000-80,000 (-17.78%)0.53%$1 MNov 10, 2026
23Jane Street Group, LLC296,712+124,300 (+72.09%)0.43%$1 MNov 12, 2026
24Driehaus Capital Management LLC279,9090 (0.00%)0.40%$1 MNov 16, 2026
25Vanguard Fiduciary Trust Co274,892+13,416 (+5.13%)0.40%$1 MNov 13, 2026
Show all 84: investors 26 to 84
Institutional investors 26 to 84 in PepGen Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26Connor, Clark & Lunn Investment Management Ltd.249,369+137,298 (+122.51%)0.36%$1 MNov 10, 2026
27State Street Corp220,990-8,400 (-3.66%)0.32%$1 MNov 12, 2026
28Artia Global Partners LP205,3240 (0.00%)0.30%$0 MNov 16, 2026
29Qube Research & Technologies Ltd199,551+100,970 (+102.42%)0.29%$0 MNov 13, 2026
30Dimensional Fund Advisors LP181,151+127,038 (+234.76%)0.26%$0 MNov 4, 2026
31Brendel Financial Advisors LLC126,321New0.18%$0 MNov 9, 2026
32Palumbo Wealth Management LLC119,144New0.17%$0 MNov 13, 2026
33Squarepoint Ops LLC117,215-411,868 (-77.85%)0.17%$0 MNov 9, 2026
34Simplex Trading, LLC109,211New0.16%$0 MNov 4, 2026
35Schonfeld Strategic Advisors LLC99,510New0.14%$0 MNov 16, 2026
36Northern Trust Corp96,663-2,075 (-2.10%)0.14%$0 MNov 16, 2026
37XTX Topco Ltd95,903-149,444 (-60.91%)0.14%$0 MNov 16, 2026
38RBF Capital, LLC95,0420 (0.00%)0.14%$0 MNov 13, 2026
39Goldman Sachs Group Inc94,788-73,322 (-43.62%)0.14%$0 MNov 16, 2026
40Bridgeway Capital Management, LLC92,276-1,424 (-1.52%)0.13%$0 MNov 16, 2026
41Jacobs Levy Equity Management, Inc86,631New0.13%$0 MNov 16, 2026
42Empowered Funds, LLC84,576New0.12%$0 MNov 13, 2026
43Axq Capital, LP81,674New0.12%$0 MNov 12, 2026
44Verdad Advisers, LP59,280-7,600 (-11.36%)0.09%$0 MNov 16, 2026
45Quadrature Capital Ltd56,641+15,705 (+38.36%)0.08%$0 MNov 13, 2026
46Jump Financial, LLC46,925New0.07%$0 MNov 13, 2026
47American Century Companies Inc42,6010 (0.00%)0.06%$0 MNov 12, 2026
48Barclays PLC40,676+36,287 (+826.77%)0.06%$0 MNov 6, 2026
49Rangeley Capital, LLC39,499-30,501 (-43.57%)0.06%$0 MNov 16, 2026
50Citigroup Inc35,341+33,714 (+2072.16%)0.05%$0 MNov 4, 2026
51Rathbones Group PLC32,0030 (0.00%)0.05%$0 MNov 12, 2026
52UBS Group AG29,189-81,484 (-73.63%)0.04%$0 MNov 10, 2026
53Point72 Asset Management, L.P.22,726-16,994 (-42.78%)0.03%$0 MNov 16, 2026
54HRT Financial LP22,677New0.03%$0 MNov 13, 2026
55Vanguard Personalized Indexing Management, LLC21,166+3,537 (+20.06%)0.03%$0 MNov 16, 2026
56Two Sigma Securities, LLC19,936New0.03%$0 MNov 16, 2026
57Balyasny Asset Management L.P.19,008New0.03%$0 MNov 16, 2026
58Catalyst Funds Management Pty Ltd18,749New0.03%$0 MNov 12, 2026
59Bronte Capital Management Pty Ltd.17,7760 (0.00%)0.03%$0 MNov 12, 2026
60Vanguard Global Advisers, LLC17,7230 (0.00%)0.03%$0 MNov 13, 2026
61Two Sigma Investments, LP17,642-48,626 (-73.38%)0.03%$0 MNov 16, 2026
62Hudson Bay Capital Management LP17,407New0.03%$0 MNov 13, 2026
63Brevan Howard Capital Management LP16,921New0.02%$0 MNov 16, 2026
64Morgan Stanley12,807-36,035 (-73.78%)0.02%$0 MNov 13, 2026
65China Universal Asset Management Co., Ltd.12,637+1,629 (+14.80%)0.02%$0 MOct 28, 2026
66Spark Investment Management LLC12,100New0.02%$0 MNov 13, 2026
67Virtu Financial LLC10,695New0.02%$0 MNov 17, 2026
68WINTON GROUP Ltd10,400New0.01%$0 MNov 12, 2026
69Jpmorgan Chase & Co9,152+4,096 (+81.01%)0.01%$0 MNov 12, 2026
70Royal Bank Of Canada8,939+8,878 (+14554.10%)0.01%$0 MNov 16, 2026
71Zurcher Kantonalbank (Zurich Cantonalbank)6,111+1,627 (+36.28%)0.01%$0 MNov 10, 2026
72Group One Trading LLC5,343-4,400 (-45.16%)0.01%$0 MNov 10, 2026
73Tower Research Capital LLC (TRC)4,811-746 (-13.42%)0.01%$0 MNov 16, 2026
74Mirae Asset Global Investments Co., Ltd.3,539+445 (+14.38%)0.01%$0 MOct 29, 2026
75BNP Paribas Financial Markets2,393-304 (-11.27%)0.00%$0 MNov 12, 2026
76FMR LLC1,6640 (0.00%)0.00%$0 MNov 10, 2026
77GF Fund Management Co. LTD.1,552+125 (+8.76%)0.00%$0 MOct 26, 2026
78Rialto Wealth Management, LLC599+281 (+88.36%)0.00%$0 MNov 16, 2026
79Bare Financial Services, Inc3270 (0.00%)0.00%$0 MNov 4, 2026
80Burk Holdings LLC278New0.00%$0 MNov 5, 2026
81Nisa Investment Advisors, LLC1950 (0.00%)0.00%$0 MOct 20, 2026
82Cornerstone Financial Management LLC1210 (0.00%)0.00%$0 MNov 10, 2026
83Osaic Holdings, Inc.71New0.00%$0 MNov 12, 2026
84Caitong International Asset Management Co., Ltd66+53 (+407.69%)0.00%$0 MOct 29, 2026

Superinvestors holding PepGen Inc.

1 of the well-known investors value.today follows, from their newest Form 13F.

Mutual funds holding PepGen Inc.#

16 funds hold shares worth $5 M (about 2.5% of the company). Since their previous reports 6 added shares and 10 sold, selling $0 M net.
Mutual funds holding PepGen Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.1.41 M$3 M1.1%<0.01%no changeJun 30, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.480,909$1 M0.39%<0.01%−0.4%Jun 30, 2026
🇺🇸 iShares Biotechnology ETFBlackRock Fund Advisors448,519$1 M0.37%<0.01%−0.6%Jun 30, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC230,248$0 M0.19%<0.01%−0.8%May 31, 2026
🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors140,776$0 M0.11%0.02%+39%Jun 30, 2026
🇺🇸 Ultra-Small Company Market FundBridgeway Capital Management, LLC86,000$0 M0.07%0.10%+139%Jun 30, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC86,249$0 M0.07%<0.01%no changeMay 31, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC69,170$0 M0.06%<0.01%−7.9%May 31, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC42,675$0 M0.03%<0.01%no changeMay 31, 2026
🇺🇸 Avantis U.S. Small Cap Equity ETFAmerican Century ETF Trust42,601$0 M0.03%<0.01%+29%May 31, 2026
🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc.26,673$0 M0.02%<0.01%no changeJun 30, 2026
🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc.19,889$0 M0.02%<0.01%no changeJun 30, 2026
🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC9,517$0 M<0.01%<0.01%+31%Jun 30, 2026
🇺🇸 JNL/DFA U.S. Small Cap FundJackson National Asset Management, LLC5,789$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC1,319$0 M<0.01%<0.01%+13%Jun 30, 2026
🇺🇸 Knights of Columbus U.S. ALL CAP INDEX FUNDKnights of Columbus Asset Advisors LLC237$0 M<0.01%<0.01%+6.3%Jul 31, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 16 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at PepGen Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$43.1 M
1 purchase, 1 insider
Sold, 12 months
$59 K
7 sales, 4 insiders
Net, 12 months
$43.1 M
open market only
Insiders on file
15
since
$43.1 M-$552 K$0Nov 2023: bought $7 K (1 trades), sold $0 (0 trades)Nov 23Feb 2024: bought $27.2 M (1 trades), sold $0 (0 trades)May 2024: bought $0 (0 trades), sold $134 K (1 trades)MayJun 2024: bought $0 (0 trades), sold $354 K (5 trades)Jul 2024: bought $0 (0 trades), sold $552 K (7 trades)JulFeb 2025: bought $0 (0 trades), sold $5 K (2 trades)Apr 2025: bought $61 K (2 trades), sold $0 (0 trades)AprMay 2025: bought $10 K (1 trades), sold $0 (0 trades)Sep 2025: bought $30.6 M (2 trades), sold $0 (0 trades)SepMar 2026: bought $0 (0 trades), sold $58 K (6 trades)May 2026: bought $0 (0 trades), sold $2 K (1 trades)MayNov 2026: bought $43.1 M (1 trades), sold $0 (0 trades)
Bought (open market)Sold (open market)Hover a month for the totals
PepGen Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Ra Capital Management, L.P.Director, 10% ownerBuyindirect+8.63 M$5.000$43.1 M27.18 MForm 4
filed Kasra KasraianChief Technical OfficerSell10b5-1 plan-1,233$1.410$2 K50,074Form 4
filed James G. McArthurPresident and CEO, DirectorSell10b5-1 plan-5,144$6.230$32 K296,457Form 4
filed Paul StreckEVP, Head of R&DSell10b5-1 plan-1,832$6.230$11 K76,273Form 4
filed Noel DonnellyChief Financial OfficerSell10b5-1 plan-2,032$6.230$13 K111,655Form 4
filed James G. McArthurPresident and CEO, DirectorSell10b5-1 plan-131$6.330$829296,326Form 4
filed Noel DonnellyChief Financial OfficerSell10b5-1 plan-52$6.330$329111,603Form 4
filed Paul StreckEVP, Head of R&DSell10b5-1 plan-47$6.290$29676,226Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: PepGen Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
3.4 M
4.9% of shares · 2.83 days to cover
Shares sold short, last 24 reportsAll stocks →

Stock splits: 1-for-1.02 reverse split ; 1.018-for-1 split in the period to

Trading halts

  • 2026-11-10 11:56 UTC, code T3, resumed 12:30 UTC
  • 2026-03-30 20:01 UTC, code T3, resumed 20:35 UTC
  • 2026-03-04 21:01 UTC, code T3, resumed 21:25 UTC
  • 2025-02-24 14:30 UTC, code LUDP, resumed 14:35 UTC

Fails to deliver

  • : 64 shares at $2.52
  • : 56,548 shares at $2.36
  • : 297 shares at $2.72
  • : 1,096 shares at $2.98
  • : 100 shares at $2.97

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

PepGen Inc. scorecard#

Passes 2 of the 11 checks that could be worked out: strongest in valuation (1 of 4), weakest in profitability (0 of 3). Fiscal year 2025; market cap of Oct 26, 2026.

  • Valuation1 of 4
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✓Price to book below its peers' median1.2×Price to book 1.2× against Biotechnology's median of 2.9×.
    • –Price to sales below its peers' medianNo Price to sales on file.
    • ✗Free cash flow yield above 5%-46.9%Free cash flow is -46.9% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth0 of 1
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-2.12 vs -2.85Diluted EPS -2.12 in fiscal 2025 against -2.85 the year before (report's currency).
    • –Net income higher than five years earlierNet income of five years earlier is not on file.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 3
    • ✗Profitable in the newest year-$90 MNet income -$90 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • –Operating margin above its peers' medianNo operating margin on file.
    • ✗Return on equity above 15%-67.4%-67.4% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health1 of 2
    • ✓Short-term assets cover short-term liabilities11.9×Current ratio 11.93 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year33.7%Diluted shares up 33.7% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

PepGen Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

PepGen Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021
Income statement
Research and development7176685419
General and administrative232117148.1
Operating expenses9498856827
Operating income−94−98−85−68−27
Interest and finance income4.07.16.42.8—
Other non-operating income (expense)4.07.16.22.9−0.2
Income before tax−90−91−79−65−27
Income tax0.0−0.60.13.7r0
Net income attributable to shareholders−90−90−79−69−27
Earnings per share, basic-2.12-2.85-3.30-4.42-30.27
Earnings per share, diluted-2.12-2.85-3.30-4.42-30.27
Shares, weighted average (basic)423224160.9
Shares, weighted average (diluted)423224160.9
Balance sheet
Cash and cash equivalents614981182133
Short-term investments8871300—
Other current assets2.53.62.34.3r2.3
Current assets151124113186140
Property, plant and equipment1.93.74.83.30.6
Right-of-use (leased) assets19212427—
Total assets174151143217144
Accounts payable0.81.81.01.43.2
Current liabilities1317181910
Lease liabilities (non-current)14161719—
Total liabilities2632353811
Retained earnings−361−271−181−103−34
Shareholders' equity147119108180−32
Total liabilities and equity174151143217144
Shares outstanding693324241.0
Cash-flow statement
Depreciation and amortization1.41.51.20.50.2
Share-based compensation11117.04.81.5
Cash from operating activities−82−82−69−59−23
Capital expenditure−0.3−0.5−2.6−3.8−0.5
Cash from investing activities−15−38−32−3.8−0.5
Shares issued—9.9—114—
Cash from financing activities10889−0.2112148
Change in cash11−31−10149125
Report10-K10-K10-K10-K/A10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Events at PepGen Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.

Directors and officers 4 · Material agreement 2 · Shareholder vote 2 · Results announced 9

PepGen Inc.: events reported to the SEC
FiledWhat happenedFiling
Material agreement8-K
Results announced8-K
Results announced8-K
Shareholder vote8-K
Results announced8-K
Results announced8-K
Results announced8-K
Directors and officers8-K
Material agreement8-K
Results announced8-K
Shareholder vote8-K
Results announced8-K
Directors and officers8-K
Directors and officers8-K
Results announced8-K
Results announced8-K
Directors and officers8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026

Acquisitions and funding#

2 private funding rounds before listing

Private share sales · funding history

Private share sales of PepGen Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jul 2021$113 MNo. 2$50 to $250 million15equitySEC
Nov 2020$14 MNo. 1$10 to $50 million6equity, optionsSEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

H-1B hiring at PepGen Inc.#

3 labor condition applications certified in fiscal 2024 for 3 positions, at a median wage of $177 K a year.

Certified, FY2024
3
#1,404 among companies on value.today
Worker positions
3
Median wage offered
$177 K
a year, full-time
Applications filed
3
PepGen Inc.: most frequent H-1B job titles in fiscal 2024
Job titlePositionsMedian wage offered
Director, Regulatory StrategistRegulatory Affairs Managers1$230 K
Principal Scientist, Associate DirectorBiochemists and Biophysicists1$177 K
Sr. Specialist, Quality AssuranceRegulatory Affairs Specialists1$110 K

Where: Boston, MA 3

PepGen Inc.: labor condition applications by fiscal year
Fiscal yearCertifiedPositionsMedian wageFiled
FY202433$177 K3
FY202311$255 K1
FY202222$155 K2

Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as PepGen Inc.

How PepGen Inc. compares in Biotechnology

  • Market cap$175 M · higher than 42% of 726
  • Price / book1.2× · lower than 76% of 534
  • FCF yield-46.9% · higher than 25% of 449

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
PepGen Inc.🇺🇸$175 M———
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 26, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at PepGen Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show PepGen Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about PepGen Inc.? Suggest a correction